

4th July, 2022

- | | |
|--|---|
| (1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087 | (2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5 th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ |
| (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg | |

Sub: US FDA product-specific Pre-Approval Inspection


We hereby notify that the United States Food and Drug Administration ("US FDA") conducted a Pre-Approval Inspection ("PAI") at the Company's Indore plant from 27th June 2022 to 1st July 2022. The Company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at the said plant. There is no data integrity observation.

The PAI is part of the routine business operations and the Company is committed to addressing these observations and will submit its response to US FDA within the stipulated time.

This information is being intimated to the Stock Exchanges as part of the good corporate governance and on a voluntary basis.

Kindly take the above information on record.

Thanking you,
Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary



Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380